NERM
RVNC

New England Research & Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

New England Research & Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,875
Closed -$225K – 174
2023
Q2 		$225K Buy
+8,875
New +$276K 0.13% 129

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

New England Research & Management's RVNC Position: Q3 2023 in Review

New England Research & Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 8,875 shares — an estimated $225K sold.

New England Research & Management first reported a position in RVNC in Q2 2023 and held it in 1 quarter. The position peaked at $225K in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • New England Research & Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • New England Research & Management sold 8,875 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $225K.
  • New England Research & Management first reported a position in Revance Therapeutics, Inc. in Q2 2023 and held it in 1 quarter.
  • New England Research & Management's Revance Therapeutics, Inc. position peaked at $225K in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on New England Research & Management's 13F filing for Q3 2023, filed 10 Oct 2023.